Takeda Pharmaceutical CO LTD Form 4 insider transactions

Awny Samaan Botros Farajallah, Chief Medical Officer of Takeda Pharmaceutical Co Ltd, sold 14,006 shares of common stock on August 10, 2026 for $17.10 per share.

Ramy Riad Ahmed Ibrahim, President, PDT BU of Takeda Pharmaceutical Co Ltd, sold 7,277 shares of common stock on August 10, 2026 for $17.10 per share.

Rhonda Janice Pacheco, President, U.S. Business Unit of Takeda Pharmaceutical Co Ltd, sold 16,901 shares of common stock on August 10, 2026 for $17.10 per share.

Lauren Rusckowski Duprey, Chief Transformation Officer of Takeda Pharmaceutical Co Ltd, sold 47,586 shares of common stock on August 10, 2026 for $17.10 per share.

Andrew Stewart Plump, President, R&D and a Director of Takeda Pharmaceutical Co Ltd, sold 165,393 shares of common stock on August 10, 2026 for $17.10 per share.

Agosti Marcello Pignagnoli, Head, Strat. & Port. Dev of Takeda Pharmaceutical Co Ltd, sold 22,957 shares of common stock on August 10, 2026 for $17.10 per share.

Teresa Marie Bitetti, President, OBU of Takeda Pharmaceutical Co Ltd, sold 50,012 shares of common stock on August 10, 2026 for $17.10 per share.

Elaine Mary Shannon, Pres., Global Supply & Quality of Takeda Pharmaceutical Co Ltd, sold 3,978 shares of common stock on August 10, 2026 for $17.10 per share.

Gabriele Ricci, Chief Data & Tech. Officer of Takeda Pharmaceutical Co Ltd, sold 25,088 shares of common stock on August 10, 2026 for $17.10 per share.

Nicola Deidre Petal Greenway, Chief Human Resources Officer of Takeda Pharmaceutical Co Ltd, sold 6,774 shares of common stock on August 10, 2026 for $17.10 per share.

Julie So-Young Kim, President and CEO and a Director of Takeda Pharmaceutical Co Ltd, sold 89,090 shares of common stock on August 10, 2026 for $17.10 per share.

Giles Richard Platford, President, IBU of Takeda Pharmaceutical Co Ltd, sold 31,083 shares of common stock on August 10, 2026 for $17.10 per share.

Natalie Anne Marie Furney, Global General Counsel of Takeda Pharmaceutical Co Ltd, sold 30,868 shares of common stock on August 10, 2026 for $17.10 per share.

Elaine Mary Shannon, Pres., Global Supply & Quality of Takeda Pharmaceutical Co Ltd, sold 20,363 shares of common stock on August 11, 2026 for $17.55 per share.

Nicola Deidre Petal Greenway, Chief Human Resources Officer of Takeda Pharmaceutical Co Ltd, sold 34,603 shares of common stock on August 10, 2026.

Takeda Pharmaceutical Co Ltd Director Steven Gillis has reported transactions involving ordinary shares and American Depositary Shares, including the acquisition of restricted stock units and tax obligation awards.

Takeda Pharmaceutical Co Ltd Director John Maraganore reported transactions involving ordinary shares and American Depositary Shares, including the acquisition of restricted stock units and tax obligation awards.

Kimberly A. Reed, a Director at Takeda Pharmaceutical Co Ltd, reported transactions involving ordinary shares and American Depositary Shares, including the acquisition of restricted stock units and tax obligation awards.

Takeda Pharmaceutical Co Ltd Director Masami Iijima has reported transactions involving ordinary shares and restricted stock units, including acquisitions and dispositions.

Takeda Pharmaceutical Director Bruce D. Broussard reported transactions involving restricted stock units and tax obligation awards.

Paulus Stoffels, a Director at Takeda Pharmaceutical, was granted restricted stock units and a tax obligation award on July 1, 2026.

Takeda Pharmaceutical Co Ltd Director Koichiro Kimura acquired 1,800 ordinary shares and was awarded 1,937 Tax Obligation Awards.

Takeda Pharmaceutical Co Ltd Director Miki Tsusaka reported transactions involving ordinary shares and restricted stock units.

Takeda Pharmaceutical Co Ltd executive Asuka Miyabashira has reported transactions involving ordinary shares and tax obligation awards.

Takeda Pharmaceutical Co Ltd Chief Financial Officer Milano Furuta has reported transactions involving ordinary shares and awards, including the acquisition of restricted stock units and the sale of shares to cover tax obligations.

Takeda Pharmaceutical Co. Ltd. executive Giles Richard Platford acquired 49,558 American Depositary Shares through an award of restricted stock units.

Takeda Pharmaceutical Co. Ltd. Chief Commercial & Government Officer Jennifer Marie Smoter acquired 18,808 American Depositary Shares through restricted stock units.

Ramy Ibrahim, President of PDT BU at Takeda Pharmaceutical Co Ltd, acquired 25,078 American Depositary Shares through an RSU award.

Nicola Deidre Deidre Greenway, Chief Human Resources Officer at Takeda Pharmaceutical Co Ltd, acquired 22,570 American Depositary Shares through restricted stock units.

Takeda Pharmaceutical Co Ltd Chief Medical Officer Awny Samaan Botros Farajallah reports an award of 17,554 Restricted Stock Units (RSUs).